Among the rare blood disorder drugs, Alprolix sales rose 7.8% to €135 million. Eloctate sales declined 12.4% to €30 million in the quarter due to patients switching to the new drug Altuviiio. New drug Enjaymo recorded sales of €17 million in the quarter compared with €16 million in the previous quarter.